st.subheader("ğŸŒ WHO ê³µì‹ ê¶Œê³  Â· GLP-1 ì ‘ê·¼ì„± ë³´ê±´ ê¸°ì‚¬")

st.markdown("""
### ğŸ“° ì£¼ìš” ë³´ê±´ ê¸°ì‚¬ (ë¦¬ë·° ë° ì›ë¬¸ ë³´ê¸°)

ğŸ”— **WHO backs use of GLP-1 therapies for obesity, warns access will remain limited (Reuters)**  
ğŸ‘‰ WHOì—ì„œ GLP-1 ê³„ì—´ ì•½ë¬¼ì„ **ë¹„ë§Œ ì¹˜ë£Œ ëŒ€ìƒìœ¼ë¡œ ê³µì‹ ê¶Œê³ **í–ˆì§€ë§Œ, **ì ‘ê·¼ì„±ì— í•œê³„ê°€ ë‚¨ì•„ ìˆìŒì„ ê²½ê³ **í•˜ëŠ” ê¸°ì‚¬ì…ë‹ˆë‹¤.  
[ê¸°ì‚¬ ë°”ë¡œ ë³´ê¸°](https://www.reuters.com/business/healthcare-pharmaceuticals/who-backs-use-glp-1-therapies-obesity-warns-access-will-remain-limited-2025-12-01/) :contentReference[oaicite:0]{index=0}

---

### ğŸ“œ WHO ê³µì‹ ìë£Œ (ê¸€ë¡œë²Œ ê°€ì´ë“œë¼ì¸)

ğŸ”— **WHO guideline on the use of GLP-1 therapies for obesity (ê³µì‹ ì„¤ëª…)**  
ğŸ‘‰ WHO ê³µì‹ ì›¹ì‚¬ì´íŠ¸ì—ì„œ ë°œí‘œí•œ ë¹„ë§Œ ì¹˜ë£Œìš© GLP-1 ì¹˜ë£Œ ê°€ì´ë“œë¼ì¸ ìš”ì•½ì…ë‹ˆë‹¤.  
[ê°€ì´ë“œë¼ì¸ ë³´ê¸° (WHO)](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) :contentReference[oaicite:1]{index=1}

---

### ğŸ“„ í•µì‹¬ ìš”ì•½
- WHOëŠ” GLP-1 ì¹˜ë£Œì œë¥¼ **ì„±ì¸ ë¹„ë§Œ ì¹˜ë£Œ ì˜µì…˜ìœ¼ë¡œ ì¡°ê±´ë¶€ ê¶Œê³ **í–ˆìŠµë‹ˆë‹¤. :contentReference[oaicite:2]{index=2}  
- ì´ ê¶Œê³ ëŠ” **ì¥ê¸° ì¹˜ë£Œì™€ ìƒí™œìŠµê´€ ê°œì„  ë³‘í–‰**ì´ í•„ìš”í•˜ë‹¤ê³  ëª…ì‹œí•©ë‹ˆë‹¤. :contentReference[oaicite:3]{index=3}  
- **ë¹„ìš©, ê±´ê°• ì‹œìŠ¤í…œ ì¤€ë¹„, ì ‘ê·¼ì„± ê²©ì°¨** ê°™ì€ ë¬¸ì œì ë“¤ë„ í•¨ê»˜ ì–¸ê¸‰ëìŠµë‹ˆë‹¤. :contentReference[oaicite:4]{index=4}

ğŸ“Œ ì´ ë§í¬ë“¤ì€ ë¸Œë¼ìš°ì €ì—ì„œ ì—´ì–´ë³¼ ìˆ˜ ìˆë„ë¡ ì œê³µë©ë‹ˆë‹¤.
""")
